Search hospitals > California > Marysville

Fremont - Rideout Cancer Center

Claim this profile
Marysville, California 95901
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
118 reported clinical trials
16 medical researchers
Photo of Fremont - Rideout Cancer Center in MarysvillePhoto of Fremont - Rideout Cancer Center in Marysville

Summary

Fremont - Rideout Cancer Center is a medical facility located in Marysville, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Fremont - Rideout Cancer Center is involved with conducting 118 clinical trials across 260 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, Joseph M. Tuscano, Mamta Parikh, and Jonathan W. Riess.

Area of expertise

1Cancer
Global Leader
Fremont - Rideout Cancer Center has run 44 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Fremont - Rideout Cancer Center has run 27 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Fremont - Rideout Cancer Center

Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Cancer
Squamous Cell Carcinoma
Colorectal Cancer
Multiple Myeloma
Lung Carcinoma
Bladder Cancer
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This study is evaluating whether a drug called crizotinib may help treat patients with non-small cell lung cancer.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue. Standard chemotherapy used in this trial consists of combinations of the following drugs: cisplatin, carboplatin, paclitaxel, pemetrexed, and etoposide. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help tumor cells multiply. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding SBRT to the standard treatment of IGRT with chemotherapy and immunotherapy may be more effective at treating patients with inoperable non-small cell lung cancer than giving the standard treatment alone.
Recruiting2 awards Phase 314 criteria
Image of trial facility.

Sotorasib

for Non-Small Cell Lung Cancer

This study is evaluating whether a drug called AMG 510 can help treat non-small cell lung cancer.
Recruiting2 awards Phase 219 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Fremont - Rideout Cancer Center?
Fremont - Rideout Cancer Center is a medical facility located in Marysville, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Fremont - Rideout Cancer Center is involved with conducting 118 clinical trials across 260 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, Joseph M. Tuscano, Mamta Parikh, and Jonathan W. Riess.